Chronic venous insufficiency
ICD-10 I87.2 · ICD-11 BD74

Symptomatic Varicose Veins Without Truncal Reflux When Conservative Therapy Has Not Worked

This protocol applies to adults with symptomatic varicose veins of the lower extremities in whom duplex imaging confirms the absence of truncal vein reflux, and whose prior conservative therapy course did not achieve adequate control of leg discomfort or edema.

Clinical scenario

Adults with symptomatic varicose veins without truncal vein reflux who remain sufficiently symptomatic to warrant escalation beyond conservative measures.

Why escalation is needed — prior line failure

A full course of conservative therapy — comprising compression therapy, venotonic medications, lifestyle changes, and weight loss where applicable — was completed but failed to achieve the target goals of reduced leg discomfort and reduced volume of edema.

Next-line approach (partial overview)

After failure of conservative therapy, the evidence-based next step involves a procedural vein intervention combined with continued conservative management. The full treatment algorithm and specific procedural options are detailed in the protocol.

Treatment success is assessed at 8 weeks, targeting a meaningful reduction in residual varicose veins and a clinically significant improvement in symptoms as measured by the Venous Clinical Severity Score (VCSS).

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jscai.2025.103729

  1. For patients with symptomatic varicose veins without truncal vein reflux, the SCAI guideline panel suggests foam sclerotherapy plus conservative management rather than conservative management alone (conditional recommendation, very low certainty of evidence).
  2. For patients with symptomatic varicose veins without truncal vein reflux, the SCAI guideline panel suggests phlebectomy plus conservative management rather than conservative management alone (conditional recommendation, very low certainty of evidence).
  3. Two RCTs comparing polidocanol 1% vs placebo found that treatment was associated with fewer residual varicose veins (RR, 0.19; 95% CI, 0.13-0.29) and an improvement in symptoms at 8 weeks (VCSS MD, 3.25 lower; 95% CI, 3.9-2.6).
View source ↗